Небилонг

Quick links to important sections

Небилонг

Selected form

Method of action: Antihypertensive

Treatment option: Hypertension, Heart Failure

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Небилонг

Quick Facts

Property Description
Active ingredient Nebivolol
Form Oral Tablet
Pharmacological class Third-generation Beta-blocker
Common use Circulatory support (e.g., High Blood Pressure)
Origin Synthetic

What is Небилонг? Definition and Core Identity

Небилонг (Nebilong) is a pharmaceutical product available as an oral tablet that contains the synthetic active ingredient Nebivolol. The medicine is utilized as a cardiovascular agent for systemic support, specifically designed to influence the body’s adrenergic system.

The core of the preparation is the International Nonproprietary Name (INN) substance Nebivolol, typically formulated as the hydrochloride salt. This active molecule is administered as a racemic mixture of two enantiomers, a chemical characteristic that contributes to its overall pharmacological profile. The distinction of the Небилонг preparation is its specific formulation of the Nebivolol compound within a readily absorbable oral tablet designed for reliable daily administration.

What Type of Medicine is Nebivolol? Classification and Purpose

Nebivolol is categorized as a third-generation beta-blocker, a classification that grants it properties beyond simple heart rate reduction. It is precisely defined as a highly cardioselective beta1-adrenergic receptor antagonist.

The significance of the third-generation beta-blocker status is noted because this group is distinguished by combining traditional cardiac-slowing activity with the capacity to induce vasodilatory effects, primarily through the release of nitric oxide. This dual-action mechanism contributes to the drug's efficacy as an antihypertensive agent. Therefore, the general therapeutic purpose of Небилонг is the sustained control of elevated systemic resistance, used in the long-term support of cardiovascular health and the management of conditions like high blood pressure (Hypertension).

Regulatory References

  1. MedlinePlus on Nebivolol

What side effects are possible with Небилонг?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety characteristics of Небилонг (Nebivolol), based on government regulatory prescribing information.


Documented Adverse Reactions and Frequency

Adverse reactions are classified according to frequency, based on clinical trial data published in regulatory documents:

Classification Examples of Reactions (SOC Group)
Common (1/100) Headache, dizziness, fatigue, oedema, paraesthesia, constipation, nausea, diarrhoea.
Uncommon (1/1000) Bradycardia, depression, nightmares, visual impairment, dyspepsia, orthostatic hypotension.
Rare (1/10,000) Syncope (fainting), angioedema (swelling), hypersensitivity reactions.

These effects are grouped by System-Organ Classes, including Nervous System, Cardiac, Gastrointestinal, Vascular, and Psychiatric disorders.


Serious Safety Constraints and Special Considerations

Nebivolol is associated with serious safety constraints and limitations defined in official labeling:

  • Serious Adverse Reactions: Reactions classified as Rare, such as syncope or angioedema, are documented. Additionally, events like acute heart failure exacerbation are listed under Cardiac Disorders.
  • Contraindications: The medicine is restricted and should not be used in patients with conditions such as severe bradycardia, second- or third-degree heart block, cardiogenic shock, and severe hepatic impairment.
  • Time-Related Pattern: Regulatory documents note that adverse reactions are often transient and may be observed more frequently at the start of treatment.
  • Population-Specific Notes: Specific caution and dose adjustment may be required for use in older adults (over 70 years) and individuals with severe renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Nebivolol overdose is characterized by severe cardiovascular effects and mandates an immediate emergency response based on official documentation.

Domain Official Regulatory Statements
Documented Overdose Presentations Overdosage most commonly presents with bradycardia (slow heart rate) and hypotension (low blood pressure). Other documented manifestations include dizziness, fatigue, vomiting, and hypoglycemia.
Physiological Systems Affected Primarily affects the cardiovascular system, potentially leading to cardiac failure or heart block. Respiratory symptoms such as bronchospasm have been associated with beta-blocker overdosage.
Emergency-Response Statements Immediate medical attention is required when overdosage is suspected. Regulators advise contacting a Poison Control Center for current information on beta-blocker overdose treatment.

Official Overdose Statements

  • The most critical outcomes include cardiac failure and heart block, reflecting a severe risk to the circulatory system.
  • Management is formally described as symptomatic and supportive. There is no specific antidote known.
  • Specific beta-agonists (e.g., Dobutamine, Isoproterenol) may be administered to reverse the beta-blocking effects, though regulatory documents caution that this procedure carries a risk of protracted severe hypotension.

Connection to the overall overdose profile: The official documents define the overdose scenario by establishing the documented risk of severe cardiovascular instability. This severe outcome potential necessitates immediate emergency medical intervention. The required management focuses on reversing the critical effects and providing symptomatic support, strictly based on established regulatory protocols.

Therapeutic Uses of Небилонг

What Небилонг Treats: Main Uses and Benefits

Небилонг (Nebivolol) is a medication that provides supportive therapeutic benefit in cardiovascular care, primarily addressing conditions characterized by periods of heightened symptoms. Its therapeutic domains include the management of essential hypertension (high blood pressure) and providing support for stable, chronic heart failure in specific patient populations.

The primary indication is for the treatment of hypertension. The medication is generally applied in contexts where additional symptomatic support is needed to help address symptom clusters that may become intense or disruptive. The use in these scenarios contributes to improved comfort during symptomatic periods.

“The long-term application supports general well-being during symptomatic phases and assists with maintaining functional stability.”

Quick Fact: Support for Symptoms that Interfere with Daily Functioning.

Symptomatic Relief and Stability

Небилонг is commonly used when symptoms linked to cardiovascular stress intensify and supportive relief is needed. It helps ease the overall symptom load and supports the patient during phases of increased distress or discomfort associated with these conditions. For individuals with stable heart failure, it is relevant when symptoms interfere with routine activities, contributing to support during difficult symptomatic episodes.

Eligibility and Restrictions for Use

Population Eligibility and Non-Eligibility Status

The official regulatory profile for Небилонг (Nebivolol) defines strict constraints for patient eligibility. The medicine is formally approved for use in adults with essential hypertension. For the treatment of stable chronic heart failure, its use is approved in elderly patients (ge 70 years) as an add-on therapy.


Absolute Contraindications

Use of the medicine is strictly contraindicated (prohibited) in patients with certain severe pre-existing conditions, including severe bradycardia, cardiogenic shock, and decompensated cardiac failure. Contraindication also applies to individuals with severe hepatic impairment, metabolic acidosis, a history of bronchial asthma, or hypersensitivity to the drug substance.


Age and Conditional Restrictions

Use in children and adolescents (below 18 years) is not recommended because safety and efficacy have not been established. Use during pregnancy and lactation is generally restricted or not recommended as Nebivolol passes into breast milk. Patients with severe renal impairment or moderate hepatic impairment may be eligible but require conditional use and close monitoring due to specific organ function restrictions documented in the prescribing information.

What should I know about interactions with other medicines?

It is crucial to inform your healthcare provider about all medicines, over-the-counter drugs, vitamins, and herbal products you are currently taking before starting Nebilong (Nebivolol). Nebilong's action can be significantly affected by, or it can affect, other substances, potentially leading to serious side effects like excessively slow heart rate (bradycardia) or very low blood pressure (hypotension).

Medications to Use with Caution or Avoid

Category Examples of Interacting Medicines Potential Effect
Heart/Blood Pressure Drugs Certain Calcium Channel Blockers (e.g., verapamil, diltiazem), Class I Antiarrhythmics (e.g., quinidine, propafenone), Digitalis glycosides, other beta-blockers, and centrally acting antihypertensives (e.g., clonidine). Increased risk of severe bradycardia, heart block, or reduced heart contractility.
Drugs Affecting Metabolism CYP2D6 enzyme inhibitors (e.g., fluoxetine, paroxetine, thioridazine). May significantly increase Nebivolol blood levels, raising the risk of side effects.
Other Medications Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May counteract the blood pressure-lowering effect of Nebilong.
Volatile Halogenated Anesthetics (used in surgery) Increased risk of severe hypotension and slowed heart rate.

Consult your doctor if you are using any medications for diabetes, as Nebilong can mask symptoms of low blood sugar, such as a rapid heartbeat. Alcohol consumption may also amplify the blood pressure-lowering effect and increase the risk of dizziness.

Mechanism of Action

How Nebivolol Works: The Dual Pharmacodynamic Mechanism

Nebivolol's mechanism is defined by a dual action involving distinct receptor pathways that influence both cardiac and vascular function.

Selective Reduction of Cardiac Workload (beta1 Antagonism)

This domain covers the drug's primary action on the heart through selective beta1-adrenergic receptor blockade. The competitive antagonism limits the influence of sympathetic nervous system signals (like norepinephrine) on heart tissue, which triggers a mechanistic cascade. By interfering with this signaling, the mechanism leads to both a slowing of the heart rate (negative chronotropy) and a reduction in the force of contraction (negative inotropy). The resulting physiological effect of this domain is a direct reduction in Cardiac Output (CO).

Active Vasodilation via Endothelial Nitric Oxide (NO) Modulation

The secondary domain involves the stimulation (agonism) of beta3-adrenergic receptors found on the lining of blood vessels. This interaction activates the enzyme Endothelial Nitric Oxide Synthase (eNOS), increasing the production of the gaseous mediator Nitric Oxide (NO). Enhanced NO bioavailability causes the relaxation of vascular smooth muscle, leading to the widening of arteries. This physiological change primarily reduces the Systemic Vascular Resistance (SVR), complementing the cardiac-slowing effect.

Synergistic Hemodynamic Effect

These two distinct mechanistic domains—the reduction of cardiac output and the reduction of systemic resistance—operate concurrently. The two enantiomers of Nebivolol complement each other, with one providing the beta1 blockade and the other promoting vasodilation. The synergy results in an influence on both cardiac output and systemic vascular resistance.

Dosage and Administration Information

How to Use Небилонг (Nebivolol): Administration Guidelines

Небилонг is used strictly via the oral route as a tablet swallowed once daily. A structured approach is utilized to initiate and continue treatment, which is based on slow, individualized dose adjustments rather than fixed dosing.


Dosing Regimens

Dosing regimens vary based on the treated condition, emphasizing a low starting dose followed by gradual titration.

Indication Initial Dose Maximum Daily Dose
Hypertension 5 mg once daily Up to 40 mg once daily
Chronic Heart Failure 1.25 mg once daily 10 mg once daily

Dose increases generally occur at intervals of one to two weeks to allow the body to adjust to the medication before a further dose change is implemented. The dose used for chronic heart failure starts at the low 1.25 mg dose and is subject to slow, stepwise increments under the supervision of a physician.


Administration and Procedural Rules

Timing and Intake: The tablet is taken at the same time each day, and intake is permitted with or without food. Tablets can often be divided to facilitate the low starting doses required for certain regimens, such as the 1.25 mg dose.

Population Adjustments: A reduced starting dose of 2.5 mg once daily is applied for patients with severe renal impairment or moderate hepatic impairment.

Discontinuation: The medicine is intended for long-term use, and therapy is typically not stopped abruptly. The dose is gradually reduced over a period of approximately one to two weeks (tapering) to minimize potential issues.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Небилонг (Nebivolol)


Evidence for Use in Essential Hypertension

Research has explored the use of Небилонг in conditions characterized by elevated systemic blood pressure. The evidence base primarily consists of many short- to intermediate-term Randomized Controlled Trials (RCTs), many of which were double-blind and placebo-controlled. Regulatory agencies have also reviewed large-scale meta-analyses that combine data from multiple of these primary trials.

Researchers in these trials primarily monitored changes from baseline in seated Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP). The findings describe patterns observed in the studies where data collected for the Небилонг group showed measurements of lower blood pressure compared to those receiving the placebo. However, most original RCTs had follow-up durations that were limited to a few months, and long-term comparative evidence on major cardiovascular events (like heart attack or stroke) against all other established types of antihypertensive medicines is not fully established.


Evidence for Use in Stable Chronic Heart Failure

The research examining Небилонг for chronic heart failure is centered on one large-scale, long-term, randomized, placebo-controlled trial that monitored subjects over a period of many months. This study primarily involved patients who already had stable, mild to moderate heart failure and were receiving other standard therapies.

The research examined long-term clinical outcomes using a composite endpoint that monitored the rate of events such as All-cause Mortality and Cardiovascular Hospital Admission. The findings describe patterns observed in the studies where there were differences in the rate of the composite endpoint in the group receiving Небилонг compared to the group receiving placebo. A key limitation is that the pivotal trial cohort was restricted to elderly patients (70 years and older). Data for other age groups are still emerging, and certainty remains low for the long-term effects in younger adults with heart failure.


Associated Research: Effects on Vascular Markers and Gaps

Beyond the main indications, smaller clinical studies have explored the medicine's activity by focusing on surrogate endpoints, such as changes in endothelial function and arterial stiffness. Findings indicate patterns related to measured differences in some of these vascular markers compared to baseline or to those in comparison studies. However, this research is often based on small sample sizes and limited follow-up durations, meaning that the full clinical significance of those findings is not fully established regarding major patient outcomes.

The primary area where certainty remains low involves long-term comparative outcomes against other established drug classes for both hypertension and heart failure.

Key Studies & References

  1. Nebivolol in patients older than 70 years with chronic heart failure (SENIORS trial)
  2. Nebivolol: MedlinePlus Drug Information
  3. Guidance for Industry: Clinical Evaluation of Antihypertensive Drugs (FDA)

Frequently Asked Questions (FAQ)

Common questions about Небилонг (FAQ)


Q: Are there any long-term safety risks associated with taking Небилонг for many years?

A: This medication is typically prescribed for chronic use to help manage conditions like high blood pressure. Studies and official information caution that the medication should not be stopped suddenly, as abrupt cessation may lead to serious heart problems, such as a heart attack or severe chest pain. Any adjustments to long-term therapy are typically determined and monitored by a healthcare provider.


Q: What are the signs of an allergic reaction to Небилонг?

A: According to the official product information, signs of a serious allergic reaction (hypersensitivity) may include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat (a condition called angioedema). If any of these signs appear, contact with a healthcare provider or emergency services is typically recommended.


Q: Is it true that Небилонг can help improve blood vessel health?

A: Studies and official information indicate that this medication has mild vasodilating properties. This means the mechanism is associated with promoting the relaxation and widening of blood vessels through the nitric oxide pathway.


Q: Are there different strengths of Небилонг tablets available?

A: Yes, official regulatory documents list that the product is available in multiple tablet strengths. These typically range from lower doses like 2.5 mg up to higher doses like 20 mg or 40 mg, depending on the specific condition being treated.


Q: How long after starting Небилонг is the blood pressure expected to stabilize?

A: Official guidelines indicate that dosage adjustments are typically made in 2-week intervals to allow the body to respond to the medication and for the full effect to be established.


Q: What is the importance of taking Небилонг consistently every day?

A: The official patient information emphasizes that the medication should be taken at the same time every day. Consistency is important because it helps maintain stable levels of the medication in the bloodstream, supporting continuous blood pressure control.


Q: Does Небилонг affect sleep patterns or cause insomnia?

A: Yes, official product information lists that disturbances in sleep patterns have been reported as side effects. Adverse reactions observed in clinical trials include both trouble sleeping (insomnia) and experiencing nightmares.


Q: Does Небилонг cause weight gain?

A: In some cases, rapid weight gain is listed as a serious adverse reaction, particularly as it may be a sign of worsening heart failure. Any unusual or rapid change in weight is typically reported to a healthcare provider.


Q: What should be done if a dose of Небилонг is missed?

A: If a dose is missed, regulatory guidance suggests taking it as soon as it is remembered, unless it is close to the time of the next scheduled dose. Taking two doses at once to compensate for the missed dose is not recommended.


Q: Does Небилонг cause sexual side effects?

A: Official regulatory documents list that impotence (erectile dysfunction) has been reported as an uncommon side effect of this medication.


Q: Is it normal to experience cold hands and feet while on Небилонг?

A: The official patient labeling notes that the medication may cause or worsen symptoms of poor blood circulation. This can include feelings of coldness, numbness, or tingling in the hands and feet.


Q: Is it safe to use cold and flu medications with Небилонг?

A: Some cold and flu medications contain ingredients known as sympathomimetic agents. Official drug interaction information states that these can increase heart rate and blood pressure, potentially counteracting the effects of the prescribed medication.


Q: Does high-intensity exercise affect how Небилонг works?

A: Studies on the medication’s properties show that it is effective at reducing both heart rate and blood pressure not just at rest, but also during exercise. It continues to exert its effects even during periods of physical activity.


Q: What should be monitored while taking Небилонг, besides blood pressure?

A: Monitoring beyond blood pressure may be required for certain patients. For example, regulatory documents state that monitoring of blood glucose levels is important for patients with diabetes, and monitoring of renal function may be needed for susceptible patients.


Q: Does Небилонг interact with medications for gastric reflux (stomach acid)?

A: Yes, official drug interaction information notes a potential interaction with certain medications used for stomach acid. For example, using the H2-blocker cimetidine can increase the concentration of Небилонг in the bloodstream.

How should Небилонг be stored and disposed of?

How to Store and Dispose of Nebivolol

Nebivolol tablets must be stored at Controlled Room Temperature, which is defined by regulatory standards as 20 C to 25 C (68 F to 77 F). The product must be protected from both excess heat and moisture and should be kept from freezing.

Packaging and Safety

Regulatory labeling requires the tablets to remain in the original, tightly closed container and specifies dispensing in a light-resistant container. A mandatory requirement is to keep the medicine out of the sight and reach of children.

Disposal

Unused or expired Nebivolol must be disposed of according to local regulations. The official method is to use a community medicine take-back program. If such a program is unavailable, instructions require seeking guidance from a healthcare professional on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Небилонг found in:

A-Z Index: